2020

Peer-reviewed Publications

1. Chan V, Mazer CD, Ali FM, Quan A, Ruel M, de Varennes BE, Gregory AJ, Bouchard D, Whitlock RP, Chu MWA, Dokollari A, Mesana T, Bhatt DL, Latter DA, Zuo F, Tsang W, Teoh H, Jüni P, Leong-Poi H, Verma S. Randomized controlled trial comparing mitral valve repair with leaflet resection versus leaflet preservation on functional mitral stenosis: The CAMRA CardioLink-2 study. Circulation. 2020 Oct 6;142(14):1342-1350.
2. Garg V, Verma S, Connelly KA, Yan AT, Sikand A, Garg A, Dorian P, Zuo F, Leiter LA, Zinman B, Jüni P, Verma A, Teoh H, Quan A, Mazer CD, Ha ACT. Does empagliflozin modulate the autonomic nervous system among individuals with type 2 diabetes and coronary artery disease? The EMPA-HEART CardioLink-6 Holter analysis. Metabol Open. 2020 Jun 21;7:100039.
3. Bami K, Gandhi S, Leong-Poi H, Yan AT, Ho E, Zahrani M, Garg V, Zuo F, Teoh H, Quan A, Leiter LA, Gilbert RE, Zinman B, Thorpe KE, Jüni P, Mazer CD, Verma S, Ong G, Connelly KA. Effects of empagliflozin on left ventricular remodeling in patients with type 2 diabetes and coronary artery disease: Echocardiographic substudy of the EMPA-HEART CardioLink-6 Randomized Clinical Trial. J Am Soc Echocardiogr. 2020 May;33(5):644-646.
4. Opingari E, Verma S, Connelly KA, Mazer CD, Teoh H, Quan A, Zuo F, Pan Y, Bhatt DL, Zinman B, Leiter LA, Yan AT, Cherney DZI, Gilbert RE. The impact of empagliflozin on kidney injury molecule-1: A sub-analysis of the EMPA-HEART CardioLink-6 randomized trial. Nephrol Dial Transplant. 2020 May 1;35(5):895-897.
5. Mazer CD, Hare GMT, Connelly PW, Gilbert RE, Shehata N, Quan A, Teoh H, Leiter LA, Zinman B, Jüni P, Zuo F, Mistry N, Thorpe KE, Goldenberg RM, Yan AT, Connelly KA, Verma S. Effect of empagliflozin on erythropoietin levels, iron stores and red blood cell morphology in patients with type 2 diabetes and coronary artery disease. Circulation. 2020 Feb 25;141(8):704-707.

Conference Abstracts

1. Kosmopoulos A, Verma S, Meglis G, Verma R, Quan A, Teoh H, Verma M, Jiao L, Wang R, Kajil M, Kosiborod MN, Bari B, Berih AA, Díaz R, Mason RP, Steg PG, Simon T, Go AS, Ambrosy AP, Choi R, Kushner AM, Leiter LA, Mazer CD, Bhatt DL. First human trial of a loading dose of icosapent ethyl in patients with COVID-19: Primary results of the VASCEPA COVID-19 CardioLink-9 randomized trial.
   2020 National Lipid Association (NLA 2020) Virtual Scientific Sessions. December 12, 2020.
2. Ha ACT, Verma S, Mazer CD, Quan A, Latter DA, Yanagawa B, Wilson M, Yau TM, Jacques F, Brown CD, Singal RK, Yamashita MH, Saha T, Teoh KH, Lam B-K, Kosmopoulos A, Deyell M, Cheung CC, Garg V, Brodutch S, Teoh H, Zuo F, Thorpe KE, Jüni P, Bhatt DL, Verma A. Enhanced Monitoring For Atrial Fibrillation Following Cardiac Surgery: Primary Results Of The SEARCH-AF Randomized Trial
   Late Breaker at the Virtual 2020 American Heart Association Annual Scientific Sessions.
3. Chan V, Mazer CD, Mesana T, De Varennes BE, Gregory AJ, Bouchard D, Zuo F, Ali FM, Tsang W, Latter DA, Juni P, Teoh H, Quan A, Leong-Poi H, Verma S. A randomized surgical trial of mitral valve repair with leaflet resection versus leaflet preservation on functional mitral stenosis – primary results of the CAMRA CardioLink-2 trial.
   ESC Congress 2020 The Digital Experience.
   Eur Heart J. 2020; 41 (Suppl 2):1980.